Background: Larger maximum tumor diameter (MTD) has been associated with worse prostate cancer (PCa) outcomes. However, the impact of MTD in PCa treated with external beam radiotherapy and brachytherapy boost (EBRT+BB) remains unknown.
Materials And Methods: Patients with PCa treated with EBRT+BB were identified from an institutional database. Clinical data including MTD, age, androgen deprivation therapy (ADT) use, prostate specific antigen (PSA), International Society of Urologic Pathology (ISUP) group, clinical T-stage, and presence of adverse pathology on imaging were retrospectively collected. Multivariable and univariable cox proportional hazards models for biochemical failure (BF) and distant metastasis (DM) were produced with MTD grouped by receiver operating characteristic (ROC) cut-point. Cumulative hazard functions for BF and DM were compared with log-rank test and stratified by ISUP group.
Results: Of 191 patients treated with EBRT+BB, 113 had MTD measurements available. Larger MTD was associated with increased ADT use and seminal vesicle involvement. ROC optimization identified MTD of 24 mm as the optimal cut-point for both BF and DM. MTD was independently associated with both BF (HR 8.61, P = .048, 95% CI 1.02-72.97) and DM (HR 8.55, P = .05, 95% CI 1.00-73.19). In patients with ISUP group 4 to 5 disease, MTD > 24 mm was independently associated with increased risk of DM (HR 10.13, P = .04, 95% CI 1.13-91.12).
Conclusions: This is the first study to evaluate MTD in the setting of EBRT+BB. These results demonstrate that MTD is independently associated with BF and metastasis. This suggests a possible role for MTD in risk assessment models and clinical decision-making for men receiving EBRT+BB.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clgc.2021.10.003 | DOI Listing |
J Theor Biol
December 2024
College of Information Engineering, Zhejiang University of Technology, Hangzhou, China. Electronic address:
Metronomic chemotherapy (MCT) is a novel chemotherapy approach characterized by a high-frequency, low-dose administration strategy. The "chemo-switch" regimen involves the sequential use of two dosing strategies: maximum tolerated dose (MTD) chemotherapy and MCT. For patients with pancreatic ductal adenocarcinoma (PDAC), selecting novel chemotherapy regimens appropriately according to their physical conditions may help address the challenges associated with MTD chemotherapy, such as excessive toxicity, prolonged tumor recovery, and suboptimal efficacy.
View Article and Find Full Text PDFPharm Stat
December 2024
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Conventional Phase I trial designs assign a single dose to each patient, necessitating a minimum number of patients per dose to reliably identify the maximum tolerated dose (MTD). However, in many clinical trials, such as those involving pediatric patients or patients with rare cancers, recruiting an adequate number of patients can pose challenges, limiting the applicability of standard trial designs. To address this challenge, we propose a new Phase I dose-finding design, denoted as IP-CRM, that integrates intra-patient dose escalation with the continual reassessment method (CRM).
View Article and Find Full Text PDFContemp Clin Trials Commun
December 2024
Department of Pediatrics, Columbia University Irving Medical Center, New York, USA.
Background: Children with sickle cell anemia (SCA) in Sub-Saharan Africa are at high risk of sickle cerebrovascular injury (SCVI). Hydroxyurea, a commonly used disease-modifying therapy, may reduce SCVI resulting in potential impact on reducing stroke and cognitive dysfunction. We aim to test the impact of daily hydroxyurea therapy on these outcomes in Ugandan children with SCA.
View Article and Find Full Text PDFPurpose: Novel therapies targeting specific genomic alterations are a promising treatment approach for relapsed/refractory cancer. Patients with specific alterations may be more likely to respond. Trial designs should maximize opportunities for such patients to enroll on these trials.
View Article and Find Full Text PDFCHEST Crit Care
December 2024
Division of Pulmonary, Allergy, and Critical Care (G. L. A.), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; the Division of Pulmonary and Critical Care Medicine (S. M. S.), University of Rochester Medical Center, Rochester, NY; the Department of Anaesthesia and Critical Care (A. R., Z. F., and M. T. D. S.), Greys Hospital, KwaZulu-Natal Department of Health, the Department of Anaesthesia and Critical Care (J. I.), Harry Gwala Regional Hospital, KwaZulu-Natal Department of Health, Pietermaritzburg, the Department of Anaesthesia and Critical Care (R. D. W. and M. T. D. S.), School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa; the Faculty Medicine and Pharmacy (R. D. W.), Vrije Universiteit Brussel (VUB), Brussels, Belgium; and the Department of Intensive Care (R. D. W.), John Radcliffe Hospital, Oxford University Trust Hospitals, Oxford, England.
Background: A proposed new global definition of ARDS seeks to update the Berlin definition and account for nonintubated ARDS and ARDS diagnoses in resource-variable settings.
Research Question: How do ARDS epidemiologic characteristics change with operationalizing the new global definition of ARDS in a resource-limited setting?
Study Design And Methods: We performed a real-use retrospective cohort study among adult patients meeting criteria for the Berlin definition of ARDS or the global definition of ARDS at ICU admission in two public hospitals in the KwaZulu-Natal Department of Health, South Africa, from January 2017 through June 2022.
Results: Among 5,760 adults (aged ≥ 18 years) admitted to the ICU, 2,027 patients (35.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!